NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class (Descending) | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
61703-0350-38 | 61703-0350 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intravenous, Subcutaneous | July 27, 2005 | In Use | |
61703-0408-22 | 61703-0408 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous | Feb. 26, 2001 | Nov. 2, 2011 | In Use |
61703-0408-25 | 61703-0408 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous | Nov. 11, 2013 | In Use | |
61703-0408-41 | 61703-0408 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous | Feb. 26, 2001 | In Use | |
43598-0143-62 | 43598-0143 | Azacitidine | Azacitidine | 100.0 mg/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | April 20, 2022 | In Use | |
71288-0169-25 | 71288-0169 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Feb. 28, 2022 | In Use | |
68001-0524-30 | 68001-0524 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb. 18, 2022 | In Use | |
68001-0524-31 | 68001-0524 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb. 18, 2022 | In Use | |
68001-0525-27 | 68001-0525 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb. 18, 2022 | In Use | |
68001-0525-32 | 68001-0525 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb. 18, 2022 | In Use | |
51079-0510-05 | 51079-0510 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jan. 21, 2014 | May 31, 2022 | No Longer Used |
67184-0503-01 | 67184-0503 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 11, 2018 | In Use | |
00409-1045-01 | 00409-1045 | PEMETREXED | PEMETREXED | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 27, 2022 | In Use | |
00409-1060-01 | 00409-1060 | Pemetrexed | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 20, 2022 | In Use | |
00409-1061-01 | 00409-1061 | Pemetrexed | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 20, 2022 | In Use | |
00409-2188-01 | 00409-2188 | PEMETREXED | PEMETREXED | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 27, 2022 | In Use | |
00409-3532-01 | 00409-3532 | PEMETREXED | PEMETREXED | 1.0 g/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 27, 2022 | In Use | |
00480-4514-01 | 00480-4514 | Pemetrexed | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 31, 2022 | In Use | |
00480-4515-01 | 00480-4515 | Pemetrexed | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 31, 2022 | In Use | |
00480-4516-01 | 00480-4516 | Pemetrexed | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 1, 2022 | In Use | |
00781-3518-76 | 00781-3518 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 8, 2022 | In Use | |
00781-3519-90 | 00781-3519 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 8, 2022 | In Use | |
16729-0229-03 | 16729-0229 | Pemetrexed | Pemetrexed | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
16729-0230-11 | 16729-0230 | Pemetrexed | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
16729-0244-38 | 16729-0244 | Pemetrexed | Pemetrexed | 1.0 g/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use |
Found 10,000 results in 7 milliseconds — Export these results